FDA clears Hologic's Localizer for long-term placement

2018 07 31 22 13 5219 Hologic Rsna 2017 400

The U.S. Food and Drug Administration (FDA) has cleared women's imaging firm Hologic's Localizer radiofrequency identification (RFID) breast lesion localization device for long-term placement.

Localizer consists of an implantable tag that can be detected by a portable, handheld reader that indicates the location and distance to the lesion, the company said. The clearance allows the device to be implanted more than 30 days prior to breast-conserving surgery.

Page 1 of 3450
Next Page